Subtype
Female Reproductive System Squamous Cell Carcinoma
CI-CAN-00002689Explore in graph →
29 active trials1 evidence items
- NCIt
- C215419
Loading cancer entity…
Subtype
CI-CAN-00002689Explore in graph →
Clinical trials
107 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (7)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07061977 | Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer | recruiting | Phase 3 | 336 | National Cancer Institute (NCI)NIH | 2 | Sep 29, 2026 | clinicaltrials |
| NCT07848243 | Clinical Investigator-Initiated Trial (IIT) of PD-L1-Targeted Radionuclide Probes | recruiting | Phase 2 | 50 | Peking University Cancer Hospital & InstituteOTHER | 1 |
| Sep 29, 2026 |
| clinicaltrials |
| NCT07147361 | Predictive Biomarkers for PD-1 Inhibitor Response in Squamous Cell Carcinoma(PB-PD1R-SCC) | active not recruiting | — | 800 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07217171 | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas | recruiting | Phase 1 | 160 | EvolveImmune United, IncINDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT03074513 | Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors | active not recruiting | Phase 2 | 133 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07804966 | Sac-TMT in Vaginal and Vulvar Cancers(ARCANA) | not yet recruiting | Phase 2 | 48 | Latin American Cooperative Oncology GroupOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07602842 | A Study of IDP-001 in Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 132 | InduPro, Inc.INDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07796672 | Feasibility Study of Blood Biomarker Identification in Cervical Cancer(CLARITY) | recruiting | — | 100 | Queensland Centre for Gynaecological CancerOTHER_GOV | 1 | Sep 2, 2026 | clinicaltrials |
| NCT02466971 | Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers | active not recruiting | Phase 3 | 450 | National Cancer Institute (NCI)NIH | 3 | Aug 21, 2026 | clinicaltrials |
| NCT02978625 | Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers | active not recruiting | Phase 2 | 68 | National Cancer Institute (NCI)NIH | 1 | Aug 13, 2026 | clinicaltrials |
| NCT06543576 | External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer | recruiting | Phase 1 / Phase 2 | 35 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT06358469 | STRatIfication of Vulvar SCC by HPV and p53 Status to Guide Excision(STRIVE) | recruiting | N/A | 249 | Canadian Cancer Trials GroupNETWORK | 2 | Aug 11, 2026 | clinicaltrials |
| NCT02595879 | Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer | active not recruiting | Phase 1 | 21 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT04622670 | Yoga Therapy During Chemotherapy and Radiation Treatment for the Improvement of Physical and Emotional Well-Being in Patients With Stage IB2-IIIB Cervical Cancer | active not recruiting | N/A | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07169734 | A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors | recruiting | Phase 1 / Phase 2 | 180 | Alentis Therapeutics AGINDUSTRY | 8 | Jul 2, 2026 | clinicaltrials |
| NCT07679841 | Safety and Efficacy of Nivolumab and Imiquimod Combination in Vulvar Squamous Cell Carcinoma Patients(COLOMBE) | not yet recruiting | Phase 1 / Phase 2 | 50 | Centre Leon BerardOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT06747585 | A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors | recruiting | Phase 1 / Phase 2 | 170 | Alentis Therapeutics AGINDUSTRY | 8 | Jun 29, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT05639972 | E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers | recruiting | Phase 1 / Phase 2 | 15 | Christian HinrichsOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05686226 | E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers | recruiting | Phase 2 | 20 | Christian HinrichsOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05910827 | A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers | recruiting | Phase 1 / Phase 2 | 398 | Hummingbird BioscienceINDUSTRY | 5 | May 27, 2026 | clinicaltrials |
| NCT04430699 | Cisplatin+Pembrolizumab+RT in Vulvar Cancer | active not recruiting | Phase 2 | 24 | Massachusetts General HospitalOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT04580771 | A Vaccine (PDS0101) and Chemoradiation for the Treatment of Stage IB3-IVA Cervical Cancer, the IMMUNOCERV Trial | active not recruiting | Phase 2 | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07435376 | Intra-lesional Tumor Boost for Bulky Cervical Cancer(INTLECTUAL) | recruiting | Phase 2 | 17 | Seoul National University Bundang HospitalOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT03260023 | Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers | active not recruiting | Phase 1 / Phase 2 | 143 | TransgeneINDUSTRY | 3 | Feb 5, 2026 | clinicaltrials |
| NCT05737199 | Assessment of the Efficacy and Safety of Pembrolizumab for Ovarian Squamous Cell Carcinoma | active not recruiting | Phase 2 | 21 | Niigata University Medical & Dental HospitalOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT03983954 | Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. | active not recruiting | Phase 1 | 120 | NeoTX Therapeutics Ltd.INDUSTRY | 2 | Nov 28, 2025 | clinicaltrials |
| NCT05973487 | A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors | active not recruiting | Phase 1 | 840 | TScan Therapeutics, Inc.INDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT04574635 | Human Papilloma Virus (HPV) Circulating Tumor DNA (ctDNA) in Cervical Cancer | active not recruiting | — | 18 | Mayo ClinicOTHER | 1 | Oct 27, 2025 | clinicaltrials |
| NCT06911801 | In Vitro Study of [18F]F-FAPI-74 Feasibility in Vulvar Cancer(FAPI_VULVA_1) | not yet recruiting | — | 90 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT06505551 | Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 66 | SCG Cell Therapy Pte. Ltd.INDUSTRY | 0 | Jul 17, 2024 | clinicaltrials |
| NCT05905315 | Primary Chemoradiation VS. Neoadjuvant Chemotherapy Followed By Surgery As Treatment Strategy For LAVC(VULCANIZE-II) | recruiting | Phase 2 | 98 | The Netherlands Cancer InstituteOTHER | 1 | Apr 15, 2024 | clinicaltrials |
| NCT05613283 | Primary Cervical Cancer Screening by Self-sampling HPV Test(PREVENT) | active not recruiting | — | 17,875 | Peking University People's HospitalOTHER | 1 | Dec 21, 2023 | clinicaltrials |
| NCT04161664 | Treatment of Metastatic Vulvar Carcinoma With Carboplatin and Paclitaxel Chemotherapy(CRAVAT) | recruiting | Phase 2 | 12 | The Netherlands Cancer InstituteOTHER | 1 | Oct 19, 2022 | clinicaltrials |
| NCT04976478 | Study of Nimotuzumab Combined With IMRT in Elder Patients With Cervical Squamous Cell Carcinoma | not yet recruiting | — | 125 | Peking University Third HospitalOTHER | 1 | Jul 26, 2021 | clinicaltrials |
Data updated 17 hours agoSource updated Sep 29, 2026source: clinicaltrials